Form 4: C4 Therapeutics Director Acquires Stock Options

C4 Therapeutics Director Stephen Fawell acquired 62,000 stock options with an exercise price of $4.25, vesting in full by June 24, 2027, or the next annual meeting.

Summary

• Stephen Fawell, a Director at C4 Therapeutics, Inc., acquired 62,000 stock options on June 24, 2026.
• The options have an exercise price of $4.25 per share.
• These options are set to vest and become fully exercisable on the earlier of June 24, 2027, or the next annual meeting of the Issuer's stockholders, provided Mr. Fawell remains on the Board.
• Following this transaction, Mr. Fawell directly beneficially owns 62,000 shares of Common Stock through these options.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard compensation and incentive mechanism for a director rather than a significant strategic or financial development.

Positives

• Director acquisition of stock options can signal confidence in the company's future prospects.
• The acquisition of options at a specific exercise price indicates a potential for future value creation for the director and, by extension, shareholders.

Risks

• The vesting schedule for the options is contingent on continued service as a Board member, meaning a departure before vesting would result in forfeiture.
• The value of the options is directly tied to the future stock price of C4 Therapeutics, which is subject to market volatility and company performance.

Future Outlook

The stock options acquired by the director are exercisable upon vesting, indicating a potential future financial benefit tied to the company's stock performance.

Industry Context

StockSavvy.ai notes that the acquisition of stock options by a director is a common practice in the biotechnology sector, often used as a long-term incentive to align management's interests with those of shareholders and encourage sustained performance.

Stakeholder Impact

• Shareholders: The acquisition of options by a director may be viewed positively as it aligns director incentives with stock performance, though the direct impact is on the director's compensation.
• Employees: This transaction is part of executive compensation and does not directly impact general employee compensation or roles.
• Management: Reinforces the incentive structure for key leadership.

Next Steps

• The stock options will vest and become exercisable according to the schedule outlined.
• The director's continued service on the Board will determine the final vesting date.

Key Dates

Keywords

C4 Therapeutics, Form 4, Stock Options, Insider Trading, Beneficial Ownership, Director Compensation, Equity Award, CCCC